NICOLE BRAMWELL: Open Payments
NPI 1962084483 · TALLAHASSEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,311 in 71 payments from 9 companies in 2025. Trend: 2023 $989 · 2024 $1,195 · 2025 $1,311
Food & beverage: $1,311
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $270 |
| E.R. Squibb & Sons, L.L.C. | 17 | $248 |
| Alkermes, Inc. | 13 | $236 |
| Otsuka America Pharmaceutical, Inc. | 7 | $148 |
| Vanda Pharmaceuticals Inc. | 7 | $120 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $90 |
| ABBVIE INC. | 4 | $85 |
| Janssen Pharmaceuticals, Inc | 2 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
Products named: INGREZZA, COBENFY, ARISTADA, REXULTI, FANAPT, CAPLYTA, VRAYLAR, INVEGA SUSTENNA.
Industry payments across FL — which companies pay providers there.
